Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Authors:
- 1 April 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 10 (4) , 484
Abstract
Importance: Preventive bilateral salpingo-oophorectomy is offered to women at high risk of ovarian cancer who carry a pathogenic variant in BRCA1 or BRCA2; however, the association of oophorectomy with all-cause mortality has not been clearly defined.Objective: To evaluate the association between bilateral oophorectomy and all-cause mortality among women with a BRCA1 or BRCA2 sequence variation.Design, Setting, and Participants: In this international, longitudinal cohort study of women with BRCA sequence variations, information on bilateral oophorectomy was obtained via biennial questionnaire. Participants were women with a BRCA1 or BRCA2 sequence variation, no prior history of cancer, and at least 1 follow-up questionnaire completed. Women were followed up from age 35 to 75 years for incident cancers and deaths. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) and 95% CIs for all-cause mortality associated with a bilateral oophorectomy (time dependent). Data analysis was performed from January 1 to June 1, 2023.Exposures: Self-reported bilateral oophorectomy (with or without salpingectomy).Main Outcomes and Measures: All-cause mortality, breast cancer–specific mortality, and ovarian cancer–specific mortality.Results: There were 4332 women (mean age, 42.6 years) enrolled in the cohort, of whom 2932 (67.8%) chose to undergo a preventive oophorectomy at a mean (range) age of 45.4 (23.0-77.0) years. After a mean follow-up of 9.0 years, 851 women had developed cancer and 228 had died; 57 died of ovarian or fallopian tube cancer, 58 died of breast cancer, 16 died of peritoneal cancer, and 97 died of other causes. The age-adjusted HR for all-cause mortality associated with oophorectomy was 0.32 (95% CI, 0.24-0.42; P < .001). The age-adjusted HR was 0.28 (95% CI, 0.20-0.38; P < .001) and 0.43 (95% CI, 0.22-0.90; P = .03) for women with BRCA1 and BRCA2 sequence variations, respectively. For women with BRCA1 sequence variations, the estimated cumulative all-cause mortality to age 75 years for women who had an oophorectomy at age 35 years was 25%, compared to 62% for women who did not have an oophorectomy. For women with BRCA2 sequence variations, the estimated cumulative all-cause mortality to age 75 years was 14% for women who had an oophorectomy at age 35 years compared to 28% for women who did not have an oophorectomy.Conclusions and Relevance: In this cohort study among women with a BRCA1 or BRCA2 sequence variation, oophorectomy was associated with a significant reduction in all-cause mortality.Keywords
This publication has 27 references indexed in Scilit:
- Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriersBreast Cancer Research and Treatment, 2019
- The fallopian tube, “precursor escape” and narrowing the knowledge gap to the origins of high-grade serous carcinomaGynecologic Oncology, 2019
- Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutationGynecologic Oncology, 2019
- Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutationsCochrane Database of Systematic Reviews, 2018
- Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation CarriersJAMA Oncology, 2018
- Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutationGynecologic Oncology, 2018
- Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort StudyMayo Clinic Proceedings, 2016
- A model for estimating ovarian cancer risk: Application for preventive oophorectomyGynecologic Oncology, 2015
- Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referralBreast Cancer Research and Treatment, 2013
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010